Short answer
Syndax Pharmaceuticals Inc (SNDX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $83M (up 81.6% year over year) with net income of −$49M.
Q3 2026 key financials · XBRL
- Revenue
- $83M
- +81.6% YoY · +14.4% QoQ
- Net income
- −$49M
- +18.6% YoY · −0.1% QoQ
- Operating margin
- -50.3%
- EPS (diluted)
- −$0.55
- +20.3% YoY · +1.8% QoQ
Source: XBRL data from the Syndax Pharmaceuticals Inc (SNDX) Q3 2026 10-Q on SEC EDGAR. USD.
Syndax Pharmaceuticals Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $83.3M, up $37.4M YoY from $45.9M
- Revuforj revenue $60.7M, up 90% YoY, strongest product performance
- Niktimvo revenue $67.4M, up 47% YoY, collaboration revenue $22.6M
- Operating loss $41.9M vs $57.4M YoY, operating margin -50.3% vs -125.2%
- Cash used in operations $107.9M; financing provided $263.9M, including $250.0M convertible notes
Risk Factors
- Newly added risk: $250.0M convertible notes issued in June 2026, creating conversion-related dilution exposure through 13,631,400 shares
- Financial risk: $344.1M royalty financing liability with 13.8% Niktimvo sales participation and $822.5M payment cap
- Regulatory risk: Revuforj sales milestone triggered a $10.0M September 2026 obligation under the Vitae license
- Operational risk: Cost of product sales rose to $13.996M from $2.100M as commercial product volumes expanded
- Market risk: Niktimvo revenue participation payments reduce cash generated from U.S. product sales
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Syndax Pharmaceuticals Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.